View Biography

WANG, Zhiguo earned his PhD in cardiovascular pharmacology from the Department of Pharmacology and Therapeutics at the Faculty of Medicine & Health Sciences, McGill University, Canada. Currently, he holds the positions of Director and Professor at the Central Research Laboratories of the First Affiliated Hospital of Jinan University, China, and serves as the President and Chief Scientist of Cachine Pharmaceutical Inc., China. With a prolific academic career, he has authored 156 research articles in esteemed scientific journals, contributed to 7 monographs, and written 18 book chapters. Additionally, he has served as an editor for 1 book published by reputable scientific publishers. His research interests span various domains including cardiovascular disease and pharmacology, molecular pharmacology, epigenetic poly pharmacology, longevity, and anti-aging poly pharmacology. Notably, Wang is recognized as one of the pioneers in advancing the "one drug—multiple targets" principle of poly pharmacology, a concept elucidated in his earlier research articles and his monograph "Poly pharmacology: Principles and Methodologies". Furthermore, he introduced the groundbreaking concept of Anti-aging Poly pharmacology and advocates for a low-entropy lifestyle to foster healthy aging and longevity.
Research Interests
MicroRNA, RNA, RNA Interference, Epigenetics, Regulation of Gene Expression, RNA Biology, poly pharmacology, Cardiovascular